PT  - JOURNAL ARTICLE
AU  - Marcel Ballin
AU  - John P.A. Ioannidis
AU  - Jonathan Bergman
AU  - Miia Kivipelto
AU  - Anna Nordström
AU  - Peter Nordström
TI  - Time-Varying Death Risk After SARS-CoV-2-Infection in Swedish Long-Term Care Facilities
AID  - 10.1101/2022.03.10.22272097
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.03.10.22272097
4099  - http://medrxiv.org/content/early/2022/03/13/2022.03.10.22272097.short
4100  - http://medrxiv.org/content/early/2022/03/13/2022.03.10.22272097.full
AB  - Importance The case fatality rate of SARS-CoV-2 has been high among residents of long-term care (LTC) facilities. It is important to know if the excess mortality persists beyond the acute infection.Objective To evaluate whether SARS-CoV-2 is associated with higher mortality after the first month from documented infection.Design We extended the follow-up period of a previous, retrospective cohort study based on the Swedish Senior Alert register. LTC residents infected with SARS-CoV-2 were matched to uninfected controls using time-dependent propensity scores on age, sex, body mass index, health status, comorbidities, and prescription medication use. In a sensitivity analysis, residents were also matched on geographical region and time of Senior Alert registration.Setting LTC facilities in Sweden.Participants 3731 LTC residents with SARS-CoV-2 and 3731 controls (n=3604 in each group in the sensitivity analysis).Exposure SARS-CoV-2 infection, documented in the SmiNet register (until September 15, 2020).Main Outcome All-cause mortality over 8 months (until October 24, 2020).Results The median age was 87 years, and 65% were women. Excess mortality was highest 5 days after documented infection (hazard ratio 19.1; 95% confidence interval [CI], 14.6-24.8), after which excess mortality decreased rapidly. After the second month, the mortality rate became lower in infected residents than in controls. Median survival of uninfected controls was 577 days (1.6 years), which is much lower than national life expectancy in Sweden at age 87 (5.05 years in men, 6.07 years in women). During days 61-210 of follow-up, the hazard ratio for death was 0.41 (95% CI, 0.34-0.50) in the main analysis and 0.76 (95% CI, 0.62-0.93) in the sensitivity analysis.Conclusions and Relevance No excess mortality was observed in LTC residents who survived the acute SARS-CoV-2 infection (the first month). The life expectancy of uninfected residents was much lower than that of the general population of the same age and sex. This difference should be taken into account in calculations of years of life lost among LTC residents.Question Does SARS-CoV-2 increase mortality in residents of long-term care (LTC) facilities beyond the first month (that is, beyond the acute infection)?Findings In a matched cohort study, we found that excess mortality was high during the first month but then decreased sharply. After the second month, the mortality rate became lower in infected residents than in uninfected controls.Meaning No excess mortality was observed in LTC residents who survived the acute SARS-CoV-2 infection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors received funding used for salaries from Foundation Stockholms Sjukhem (MK), Academy of Finland (MK), Laekarsaellskapet (MK), and the Swedish Research Council (MK, AN, PN). The funders had no role in any part of this manuscript or the decision to publish.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Swedish Ethical Review Authority, which waived the informed consent requirement (no. 2020-02552)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data files used for the present study is publicly unavailable according to regulations under Swedish law, but can be applied for at each of the respective registry holders.